Biogen

Youtube Subscribe

Open: 247.67 Close: 248.39 Change: 0.72

How to get information about Biogen without reading the whole internet.

This document will help you to evaluate Biogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, drug, Alzheimers, year, Aduhelm, say, treatment, and the …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Biogen has terminated the licence agreement for the drug Aduhelm, with rights now reverting to the original owner, Swiss biopharma Neurimmune. The FDAs accelerated approval of the drug in 2021 was seen as problematic by many in the medical community. Biogen estimates potential peak revenue of $18 billion per year.

Today's News

Biogen said it terminated a licensing agreement with Neurimmune, which controls the rights to the drug. The FDAs accelerated approval of the drug in 2021 was seen as problematic by many in the medical community. Biogen also faced criticism because it was initially charging $56,000 per year for the drug, which later slashed the price in half. Biogen has terminated the licence agreement for the drug Aduhelm, with rights now reverting to the original owner, Swiss biopharma Neurimmune. Biogen will take a $60m charge in Q4 2023 as a result of dropping the programme. Biogen to halt sales and development of controversial alzheimers drug aduhelm – endpoints news. Biogen CEO Christopher A Viehbacher said in a 31 January press release that “reprioritising resources’s resources” Biogen said it has terminated the licence agreement. Biogen announced in 2022 that it would largely shut down marketing of Aduhelm. Biogen said it will turn its focus to other treatments for the fatal, mind-robbing disease. Initially priced at $56,000 a year, analysts predicted it would quickly become a blockbuster. Biogen to Realign Resources for Alzheimers Disease Franchise. Biogen will accelerate the development of potential new treatment modalities. Biogen to realign resources for alzheimers disease franchise. Biogen will discontinue the development and commercialization of ADUHELM and terminate the ENVISION clinical study into our Alzheimers franchise. Biogen to Realign Resources for Alzheimers Disease Franchise. Biogen has recorded a one-time charge of approximately $60 million related to close out costs for the program in the fourth quarter of 2023. Biogen will stop developing its Alzheimers treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple of years ago. Biogen said it will turn its focus to other treatments for the fatal, mind-robbing disease. Initially priced at $56,000 a year, analysts predicted it would quickly become a blockbuster that would generate billions for Biogen. Biogen pulls controversial Alzheimers drug Aduhelm after controversial speedy approval. Congressional report: FDA interactions with Biogen were atypical Biogen estimates potential peak revenue of $18 billion per year. Biogen is pulling the plug on the controversial drug Aduhelm, the first drug cleared by government health officials for treating Alzheimers in nearly two decades. The pharmaceutical company will give up its ownership rights to the Swiss company that invented the drug, Neurimmune. Biogen will stop developing its Alzheimers treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a couple of years ago. Biogen announced in 2022 that it would largely shut down marketing of the drug. Biogen Inc. (BIIB) Laps the Stock Market: Heres Why. Investors should also take note of any recent adjustments to analyst estimates for Biogen.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Biogen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, drug, Alzheimers, year, Aduhelm, say, treatment, and the most common words in the summary are: biogen, drug, alzheimers, aduhelm, news, best, company, . One of the sentences in the summary was: Biogen has terminated the licence agreement for the drug Aduhelm, with rights now reverting to the original owner, Swiss biopharma Neurimmune. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #drug #alzheimers #aduhelm #news #best #company.

Read more →

Youtube Subscribe

---